Drug Type T cell engagers (TCE) |
Synonyms ZL-1311 |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), MUC17 inhibitors(mucin 17, cell surface associated inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastrointestinal Neoplasms | Preclinical | China | 13 Jan 2026 |






